PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 20553253-4 2010 RESULTS: Despite fewer men with two or more adverse features (61 vs 82%; P=0.016), salvage for a rapid PSA DT vs adjuvant RT increased the risk of ACM [adjusted hazard ratio (AHR)=3.42; 95% confidence interval (CI)=1.27-9.20; P=0.015]. Thymidine 107-109 kallikrein related peptidase 3 Homo sapiens 103-106 34016556-14 2021 CONCLUSIONS: Postoperative PSA kinetics, particularly pre-SRT PSA and PSA DT, are strongly associated with adverse oncologic outcomes following SRT and should be considered in management decisions. Thymidine 74-76 kallikrein related peptidase 3 Homo sapiens 27-30 21437885-2 2011 Whether such a benefit exits in men with a protracted PSA rise in DT (>= 6 months) is unclear and was examined in the current study. Thymidine 66-68 kallikrein related peptidase 3 Homo sapiens 54-57 21437885-4 2011 Univariate and multivariate Cox regression analyses were performed to evaluate whether salvage RT in men with either a rapid (< 6 months) or a protracted (>= 6 months) PSA DT was associated with the risk of all-cause mortality adjusting for age at the time of PSA failure, known prostate cancer prognostic factors, and cardiac comorbidity. Thymidine 178-180 kallikrein related peptidase 3 Homo sapiens 174-177 18258713-4 2008 PSA-doubling time (PSA-DT) at PSA relapse influenced the outcome after PSA relapse [hazard ratio (CI): 2.000 (1.283-3.226)]; thus, on the basis of the median values of PSA-DT (>2 months) and additionally nadir PSA in previous treatment (</=2 ng/ml), patients were stratified into four groups. Thymidine 22-25 kallikrein related peptidase 3 Homo sapiens 0-3 18614274-7 2008 By contrast, PSA DT was not significantly associated with high-risk or fatal disease. Thymidine 17-19 kallikrein related peptidase 3 Homo sapiens 13-16 19720918-7 2009 Factors associated with progression to treatment among DT patients included younger age, higher clinical stage, higher Gleason score, and higher prostate-specific antigen at diagnosis. Thymidine 55-57 kallikrein related peptidase 3 Homo sapiens 145-170 16414494-12 2006 Active surveillance with selective delayed intervention based on PSA DT is a practical middle ground between radical therapy for all, which results in over-treatment of patients with indolent disease, and watchful waiting with palliative therapy only, which results in under-treatment of those with aggressive disease. Thymidine 69-71 kallikrein related peptidase 3 Homo sapiens 65-68 15681527-8 2005 The 3-year incidence of DM for patients with PSA-DT of 0 to 3, 3 to 6, 6 to 12, and more than 12 months was 49%, 41%, 20%, and 7%, respectively (P < .001). Thymidine 49-51 kallikrein related peptidase 3 Homo sapiens 45-48 16034457-2 2005 In this study, we investigated the use of a chimeric modified enhancer/promoter sequence of the human prostate-specific antigen (PSA) gene to regulate DT-A expression in human prostate cancer cells in culture, in xenografts derived from these cells, and in autochthonous tumors in TRAMP mice. Thymidine 151-153 kallikrein related peptidase 3 Homo sapiens 102-133 16170163-7 2005 Of the 28 observed prostate cancer deaths, 21 (75%) occurred in men whose PSA nadir was more than 0.2 ng/mL and who had a PSA DT of less than 3 months. Thymidine 126-128 kallikrein related peptidase 3 Homo sapiens 122-125 15681527-9 2005 Patients with PSA-DT of 0 to 3 and 3 to 6 months demonstrated a 7.0 and 6.6 increased hazard of developing DM or death, respectively, compared with patients with a DT more than 12 months. Thymidine 18-20 kallikrein related peptidase 3 Homo sapiens 14-17 12454114-6 2002 Nearly identical estimates of PCSD and all-cause death after PSA failure were noted for patients with a short PSA DT (ie, <or= 12 months). Thymidine 114-116 kallikrein related peptidase 3 Homo sapiens 61-64 12454114-6 2002 Nearly identical estimates of PCSD and all-cause death after PSA failure were noted for patients with a short PSA DT (ie, <or= 12 months). Thymidine 114-116 kallikrein related peptidase 3 Homo sapiens 110-113 12454114-8 2002 These data provide evidence to propose the hypothesis that a short posttreatment PSA DT may serve as a possible surrogate for PCSD. Thymidine 85-87 kallikrein related peptidase 3 Homo sapiens 81-84 9626230-5 1998 Rate of PSA DT was not assumed to be constant over time; it was instead allowed to vary. Thymidine 12-14 kallikrein related peptidase 3 Homo sapiens 8-11 11999465-6 2002 A combination of three parameters consisting of initial PSA level less than 10 ng/ml, WHO grade 1, one or two positive core per six to eight systematic biopsy cores with 50% or less cancer involvement significantly correlated with PSA-DT distribution in the T1c plus T2a group (P = 0.0034). Thymidine 235-237 kallikrein related peptidase 3 Homo sapiens 56-59 11999465-6 2002 A combination of three parameters consisting of initial PSA level less than 10 ng/ml, WHO grade 1, one or two positive core per six to eight systematic biopsy cores with 50% or less cancer involvement significantly correlated with PSA-DT distribution in the T1c plus T2a group (P = 0.0034). Thymidine 235-237 kallikrein related peptidase 3 Homo sapiens 231-234